Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard Gabriel Muruve
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 1.76
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -124.37
Financials
Revenue
$0.00-100.0%Net Income
$-522.4KEBITDA
$-460.6KFree Cash Flow
$-89.3KEPS (diluted)
$-0.01Shares Outstanding (diluted)
66.94M+25.7%Operating Expenses
$355.4KCash & Debt
$437.9KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-1.55M | $-0.02 |
| 2024 | $2.12M | $-3.92M | $-0.06 |
| 2023 | $1.98M | $-3.33M | $-0.05 |
| 2022 | $964.7K | $-1.41M | $-0.02 |
| 2021 | $3.89M | $-1.17M | $-0.02 |
| 2020 | $67.9K | $-4.63M | $-0.08 |
| 2019 | $93.9K | $-2.09M | $-0.04 |
| 2018 | $0.00 | $-3.02M | $-0.05 |
| 2017 | $0.00 | $-1.90M | $-0.03 |
| 2016 | $0.00 | $-1.02M | $-0.02 |
| 2015 | $37.6K | $-839.0K | $-0.02 |
| 2014 | $51.1K | $-399.0K | $-0.01 |
| 2013 | $37.7K | $-190.0K | $-0.00 |
| 2012 | $0.00 | $-329.0K | $-0.01 |
Valuation
ACHFFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
… Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company's ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”).
View source ↗
Earnings
Tue, Feb 2(in 5 months)
Consensus estimate $-0.01 per share
Typical surprise +65.5% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Mar 2$-0.02 vs $-0.01miss
- Wed, Jan 28$-0.00 vs $-0.01beat
- Tue, Sep 2$-0.00 vs $-0.01beat
- Fri, May 30$-0.01 vs $-0.01beat
Estimates and results for ACHFF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.